EU MDR Training: Regulation (EU) 2017/745 Awareness for Your Whole Team

Opens with a self-check: how would you rate your knowledge of the EU device rules, what makes a product a medical device, and which part of a device's life your role touches. Then the June 2012 European Parliament resolution on defective silicone breast implants, with about 400,000 sold worldwide and no EU-wide register, and its call for stronger notified bodies, vigilance and a European database. Explains how the MDR replaced two directives with one regulation, its application since May 2021, the 2023 extension of the transition and Eudamed coming into use module by module. Introduces Canal Orthopaedics B.V., an implant maker in Amsterdam with a distributor in Madrid and hospitals in Paris, plus a wound-dressing maker in Mumbai and a health-app developer in London. Closes with a recap and how the eleven modules and exam work.

What you will be able to do

• Explain why the EU replaced the device directives with the MDR
• Describe the MDR's main dates, from application to the transition
• Identify which part of a device's life your own role touches

Why it matters

Being able to say how your company knows its device is safe, and who checked, starts with knowing what the MDR asks.

Practice: Practice: The EU MDR at a glance · 3 questions

Begins with a distributor in Milan asked whether a fitness tracker, a dose-calculating smartphone app and coloured fashion contact lenses fall under the MDR. Explains the definition of a medical device in plain words, from instruments and software to implants, and why the purpose the manufacturer gives a product decides, not how it looks. Covers how that purpose shows in the label, instructions, sales material and clinical evaluation, and why Canal Orthopaedics puts nothing in a brochure the clinical evaluation does not support. Sets out what the MDR excludes, such as in vitro diagnostics, medicines, cosmetics and food, and the six Annex XVI groups it brings in, with a posture app in Dublin and light equipment for salons from a Paris supplier. Explains the common specifications applying from 22 June 2023, and closes with a recap.

What you will be able to do

• Decide whether a product is a medical device from its intended purpose
• Identify the main product types the MDR excludes
• Recognise Annex XVI products the MDR covers without a medical purpose

Why it matters

The purpose you claim decides the rules you meet; a single sales claim can turn a wellbeing product into a medical device.

Practice: Practice: Scope, definitions and non-medical products · 3 questions

Opens with wound dressings from a Mumbai maker going through an authorised representative in Dublin, an importer in Frankfurt and a distributor before reaching a hospital in Paris. Defines the four economic operators as Article 2 does, then the manufacturer's duties, the sole authorised representative needed by a maker outside the EU and its liability, and the checks importers and distributors make. Shows when someone else becomes the manufacturer, as when a Milan distributor sells gloves under its own brand. Covers the duty added in 2024 to give notice of a supply interruption that could cause serious harm, normally six months ahead, with a Lisbon catheter maker. Applies it all to Canal Orthopaedics, established in the Netherlands, and its distributor in Madrid checking the CE marking, declaration, labels and UDI. Closes with a recap.

What you will be able to do

• Identify the four economic operators and the duties of each
• Recognise when a distributor takes on a manufacturer's obligations
• Explain when notice of a supply interruption is required

Why it matters

If each company in the chain assumes another one checked, nobody does; knowing your role keeps unsafe devices from patients.

Practice: Practice: Manufacturers, importers and distributors · 3 questions

Starts in an operating theatre in Paris, where a Canal knee system, its reusable instruments and fracture plate screws fall into three different classes in one operation. Explains the four classes, set by intended purpose and inherent risk under the Annex VIII rules, why the manufacturer classifies its own devices, and how a dispute with a notified body is settled. Covers how duration, invasiveness and activity work across the twenty-two rules, and why the strictest rule wins. Explains Rule 8, under which implants are class IIb but joint replacements class III, and Rule 11, which classifies software by the decisions it informs. Looks at a Vienna instrument maker launching a disposable version of a reusable cutter, then the common mistakes and how to check a class against your technical documentation. Closes with a recap.

What you will be able to do

• Explain how intended purpose and risk set a device's class
• Apply the implant and software rules to simple examples
• Check a device's class against its technical documentation

Why it matters

The class decides the route to market and the evidence needed; getting it right first avoids costly rework later.

Practice: Practice: Classification · 3 questions

Opens at Canal Orthopaedics with two launches in one month: a low-class positioning aid where Canal declares conformity itself, and a class III knee system that needs a notified body. Explains conformity assessment under Annexes IX to XI, how notified bodies are designated and what they assess, and why responsibility stays with the manufacturer. Covers Article 53 and a Frankfurt maker whose application was refused, assessment of class IIb implant documentation except well-established types such as screws and plates, and certificates valid for five years at most. Then the EU declaration of conformity, drawn up under the manufacturer's sole responsibility, the CE marking rules step by step, and an importer in Brussels checking a class IIa device. Closes with a recap: assess first, declare second, mark last.

What you will be able to do

• Explain how the risk class decides the conformity assessment route
• Describe what a notified body assesses and certifies
• Check that a device has its EU declaration and correct CE marking

Why it matters

The CE marking tells a hospital who stands behind a device; knowing the route behind it helps you answer their questions.

Practice: Practice: Conformity assessment and CE marking · 3 questions

Begins with a competent authority asking Canal for evidence that its hip stem resists fatigue: one version takes weeks from a shared drive and e-mails, the other days from organised technical documentation. Explains the general safety and performance requirements of Annex One, with risks acceptable against the benefits, and how its three chapters are organised. Covers risk management for the device's whole life, with controls in a set order, illustrated by an infusion set maker in Milan whose connector can be fitted the wrong way. Looks at labels and instructions users can understand, with a Madrid distributor receiving instructions only in English. Then the six sections of the technical documentation and how long it is kept: at least ten years, fifteen for implants, with field data fed back into the risk file. Closes with a recap.

What you will be able to do

• Explain what the general safety and performance requirements ask
• Describe the order in which risk controls are applied
• Identify what the technical documentation contains and how long it is kept

Why it matters

If it is not documented, it cannot be shown; organised technical documentation lets you answer an authority in days.

Practice: Practice: Safety and performance, technical documentation · 3 questions

Opens at Canal with two views of the new knee system: a completed clinical study as the end of the job, or the start of evidence gathered every year after launch. Defines clinical evaluation as a planned, continuous process built on clinical data that give sufficient evidence of safety and performance, and how the level of evidence is justified. Covers the three tests for relying on another device's data, with a Copenhagen maker planning a bone anchor, and why implants and class III devices usually need clinical investigations. Explains post-market clinical follow-up with yearly updates and the summary for patients. Then the quality management system covering every aspect in Article 10, including outsourced sterilisation at a maker in Lisbon. Closes with a recap: evidence before launch, and every year after.

What you will be able to do

• Explain what clinical evaluation is and why it never finishes
• Describe when clinical investigations and follow-up are needed
• Identify what the quality management system must cover

Why it matters

Surgeons may spot a problem before the maker does; planned follow-up after launch keeps clinical evidence current.

Practice: Practice: Clinical evaluation and the QMS · 3 questions

Starts with a possible packaging defect in one batch of Canal hip implants, and how quickly the devices and patients can be found if every link scanned the unique identifier. Explains the UDI system, the device identifier and production identifier, the UDI carrier on labels and packaging, and the Basic UDI-DI. Covers implant cards, shown arriving with knee implants at a hospital in Brussels, and storing the UDIs of class III implants. Explains registration of manufacturers, authorised representatives and importers, the single registration number issued by the competent authority, and keeping data current, as an importer in Frankfurt must after moving office. Ends with the state of Eudamed, with four systems mandatory since May 2026, a hospital in Paris linking a stem to its patient record, and a recap.

What you will be able to do

• Explain the parts of a UDI and what each one identifies
• Describe how economic operators register and receive an SRN
• Check that a device can be traced to the patient who received it

Why it matters

Traceability cannot be added on the day of a recall; it is built in advance, one scan at a time.

Practice: Practice: UDI, EUDAMED and registration · 3 questions

Opens with a surgeon in Paris reporting a hip stem that broke inside a patient, handled in one version as a complaint for next month's meeting and in the other as a possible serious incident sent at once to vigilance. Explains the post-market surveillance system, proportionate to the risk class and part of the quality management system, and the report or PSUR depending on class. Covers serious incident reporting deadlines of fifteen, ten or two days, and field safety corrective actions with a clear notice to users, using a recall in Rome hospitals. Looks at trend reporting with an adhesive dressing maker in Hamburg receiving complaints about skin reactions. Then the person responsible for regulatory compliance, the PRRC, with the expertise and protection the MDR requires. Closes with a recap.

What you will be able to do

• Explain what a post-market surveillance system gathers and reports
• Apply the vigilance reporting deadlines to a field report
• Describe the role of the person responsible for regulatory compliance

Why it matters

Every report from the field must be assessed fast; a slow inbox uses up time that belongs to patients.

Practice: Practice: Post-market surveillance, vigilance and the PRRC · 3 questions

Opens with Regulation (EU) 2024/1860, published in July 2024, which extended the IVDR transition again because notified body capacity was not enough and tests risked shortages. Defines an in vitro diagnostic device, from reagents, calibrators and kits to instruments, software and sample tubes. Covers the four classes A to D, why every class except A now needs a notified body, and performance evaluation as the evidence. Explains the health institution exception and how a hospital laboratory in Paris that sells its own test loses it. Sets out the transition dates as amended in 2024, running to the end of 2027, 2028 or 2029 by class, with a Frankfurt maker of urine test strips that self-declared under the old directive. Shows what the IVDR shares with the MDR, with a Madrid distributor handling both, and closes with a recap.

What you will be able to do

• Explain what makes a product an in vitro diagnostic device
• Describe the four IVDR classes and which need a notified body
• Identify the IVDR transition conditions for a device

Why it matters

Tests and analysers follow their own regulation and dates; knowing which applies keeps diagnostic products on the market.

Practice: Practice: In vitro diagnostic devices: the IVDR · 3 questions

Starts with a Canal hip stem still under an old directive certificate, and a competitor whose similar stem lost the transition because it never applied for MDR certification. Explains the 2023 amendment: legacy devices placed on the market until 31 December 2027 or 31 December 2028 by class, only if a quality management system, application and written agreement were in place in time. Covers a Warsaw maker selling a legacy class IIa device during the transition. Then enforcement by national authorities, which check, inspect, act and set penalties, the four sources to follow, including guidance from the Medical Device Coordination Group, and the proposal to simplify the MDR still in the legislative process. Returns to the opening question from Module 1, what it all means for your role, and the final exam of thirty scenario questions.

What you will be able to do

• Explain the conditions a legacy device must meet during the transition
• Describe how national authorities enforce the MDR
• Identify reliable sources for following changes to the MDR

Why it matters

Missing one transition condition can take a device off the market; knowing the dates protects your products and patients.

Practice: Practice: Transition, enforcement, changes and the exam · 3 questions